Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Magnesium Vitamin B6 in First Episode of Bipolar I Disorder
NCT05837104Phase 2Recruiting
- Sponsor
- McLean Hospital
- Start
- Dec 2023
- Primary completion
- Oct 2026
- Modality
- Implantable Devices, Transdermal Patches, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in bipolar I disorder comparing Magnesium vitamin B6 with Placebo (2 arms). Primary endpoint: Change in depressive symptoms at 4 weeks. Started Dec 2023; status: recruiting.
02
Drugs
magnesiumpyridoxine
03
Conditions
bipolar I disorder
Beyond the preview
Go deeper on NCT05837104.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05837104.